← Back to guidelines
Pathology10 papers

Adnexal carcinoma of vulva

Last edited: 4/15/2026

Overview

Adnexal carcinoma of the vulva refers to malignancies originating in the vulvar glands or adjacent structures, distinct from squamous cell carcinomas arising from the squamous epithelium. Accurate diagnosis and staging are crucial for guiding treatment and predicting outcomes 1.

Diagnosis

  • Clinical Presentation: Typically presents with vulvar masses, ulceration, or abnormal bleeding 1.
  • Histopathological Examination: Essential for definitive diagnosis, including assessment of cellular morphology and architecture 1.
  • Tumor Grading: Utilize World Health Organization (WHO) grading system to assess malignancy grade 1.
  • p16/HPV Testing: Consider for prognostic value, though controversial and requires further evidence-based study 1.
  • Staging: Follow the updated FIGO staging system (2021) for accurate staging and treatment planning 1.
  • Management

  • Surgical Excision: Primary treatment often involves wide local excision with adequate margin assessment 1.
  • Lymphadenectomy: Indicated based on clinical stage and risk factors, aiming to prevent regional recurrence 1.
  • Adjuvant Therapy: Consider chemotherapy or radiotherapy for advanced stages or high-risk features 1.
  • Targeted Therapy: Not specifically detailed in provided abstracts; individualized based on molecular profiling 1.
  • Follow-Up: Regular monitoring for recurrence and late effects post-treatment 1.
  • Special Populations

  • Pregnancy: Management considerations vary; individualized care focusing on maternal and fetal safety 1.
  • Elderly Patients: Tailored treatment plans considering comorbidities and functional status 1.
  • Comorbidities: Adjust treatment strategies based on patient's overall health and coexisting conditions 1.
  • Key Recommendations

  • Implement comprehensive pathology reporting following ICCR guidelines for consistent staging and prognostication (Evidence: Strong 1).
  • Utilize the updated FIGO staging system (2021) for accurate clinical staging and treatment planning (Evidence: Strong 1).
  • Consider p16/HPV testing for prognostic assessment, acknowledging the need for further evidence (Evidence: Moderate 1).
  • References

    1 Hoang L, Webster F, Bosse T, Focchi G, Gilks CB, Howitt BE et al.. Data Set for the Reporting of Carcinomas of the Vulva: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2022. link

    Original source

    1. [1]
      Data Set for the Reporting of Carcinomas of the Vulva: Recommendations From the International Collaboration on Cancer Reporting (ICCR).Hoang L, Webster F, Bosse T, Focchi G, Gilks CB, Howitt BE et al. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists (2022)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG